Q3 Loss Narrower Than Expected at $0.40/Share, But Revenue Slips 3.1%
ICCM sits 53% above its 52-week low of $0.65 on elevated volume (8.1× avg).
Summary
IceCure posted a Q3 adjusted loss of $0.40 per share, far better than the $1.16 loss three analysts expected, and the reported net loss was $4.22 million. Revenue is the weak spot: $824.0 thousand, down 3.1% year over year and below the $876.5 thousand consensus. This lands alongside the 6-K filed today showing 9M 2026 revenue of $2.6M, up 26% year over year with U.S. sales up 83% — so the quarterly top line softened even as the full-year trend stays positive. The stock is down 48.6% this quarter and 95.5% this year, and shareholders vote November 19 on authorizing reverse splits of 5-for-1 up to 30-for-1, a proposal that underscores how thin the share price has become. The EPS beat is largely a cost line, not a demand recovery; the revenue miss is what matters for the thesis.
At the time of this announcement, ICCM was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.65 to $22.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.